Alector, Inc. (ALEC) Discusses Strategic Advances in Next Generation Neurodegeneration Therapies and Pipeline Developments Transcript

Alector, Inc. (ALEC) discussed its strategic advances in next-generation neurodegeneration therapies and pipeline developments. The company focuses on developing immune therapies for neurodegenerative diseases.

The company's lead product candidate, Acleucel, is in Phase 2b clinical trials for the treatment of frontotemporal dementia. Alector also discussed its plans to initiate a Phase 3 trial for Acleucel in 2027.